14,144
Total Claims
$2.0M
Drug Cost
1,299
Beneficiaries
$1,515
Cost/Patient
Peer Comparison vs. 18,720 Cardiology providers
-1%
Cost per patient vs peers
$1,515 vs $1,524 avg
-8%
Brand preference vs peers
12.5% vs 13.7% avg
Brand vs Generic
88% generic
Brand: 1,774 claims · $1.8M
Generic: 12,370 claims · $214K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 928 | $864K |
| Macitentan | 23 | $287K |
| Sacubitril/Valsartan | 197 | $225K |
| Rivaroxaban | 141 | $132K |
| Evolocumab | 132 | $93K |
| Empagliflozin | 85 | $65K |
| Alirocumab | 29 | $24K |
| Diltiazem Hcl | 763 | $23K |
| Dapagliflozin Propanediol | 19 | $20K |
| Ezetimibe | 492 | $18K |
| Atorvastatin Calcium | 1,584 | $17K |
| Losartan Potassium | 1,055 | $12K |
| Ranolazine | 66 | $11K |
| Icosapent Ethyl | 18 | $11K |
| Metoprolol Succinate | 482 | $8,211 |
Prescribing Profile
61
Unique Drugs
$1.3M
Patient Profile
75
Avg Age
52%
Female
1.39
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data